Your browser doesn't support javascript.
Co-infection associated with SARS-CoV-2 and their management.
Chavda, Vivek P; Patel, Aayushi B; Pandya, Anjali; Vora, Lalitkumar K; Patravale, Vandana; Tambuwala, Zara M; Aljabali, Alaa Aa; Serrano-Aroca, Ángel; Mishra, Vijay; Tambuwala, Murtaza M.
  • Chavda VP; Department of Pharmaceutics & Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, Gujarat, 380009, India.
  • Patel AB; Pharmacy Section, LM College of Pharmacy, Ahmedabad, Gujarat, 380058, India.
  • Pandya A; Department of Pharmaceutical Sciences & Technology, Institute of Chemical Technology, Mumbai, 400 019, India.
  • Vora LK; School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL, UK.
  • Patravale V; Department of Pharmaceutical Sciences & Technology, Institute of Chemical Technology, Mumbai, 400 019, India.
  • Tambuwala ZM; College of Science, University of Lincoln, Brayford Campus, Lincoln, LN6 7TS, UK.
  • Aljabali AA; Department of Pharmaceutics & Pharmaceutical Technology, Yarmouk University, Faculty of Pharmacy, Irbid, 566, Jordan.
  • Serrano-Aroca Á; Biomaterials & Bioengineering Lab, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, c/Guillem de Castro 94, Valencia, 46001, Spain.
  • Mishra V; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, 144411, India.
  • Tambuwala MM; Lincoln Medical School University of Lincoln, Brayford Campus, Lincoln, LN6 7TS, UK.
Future Sci OA ; 8(9): FSO819, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2239679
ABSTRACT
SARS-CoV-2 was discovered in Wuhan, China and quickly spread throughout the world. This deadly virus moved from person to person, resulting in severe pneumonia, fever, chills and hypoxia. Patients are still experiencing problems after recovering from COVID-19. This review covers COVID-19 and associated issues following recovery from COVID-19, as well as multiorgan damage risk factors and treatment techniques. Several unusual illnesses, including mucormycosis, white fungus infection, happy hypoxia and other systemic abnormalities, have been reported in recovered individuals. In children, multisystem inflammatory syndrome with COVID-19 (MIS-C) is identified. The reasons for this might include uncontrollable steroid usage, reduced immunity, uncontrollable diabetes mellitus and inadequate care following COVID-19 recovery.
COVID-19 infection has reported in the development several other infections and co-morbidity in patients. The present review discusses risk and management strategies in patients suffeting from co-infections caused by COVID-19 infection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Future Sci OA Year: 2022 Document Type: Article Affiliation country: Fsoa-2022-0011

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Future Sci OA Year: 2022 Document Type: Article Affiliation country: Fsoa-2022-0011